Home Overview Press Room Blog Publications For Students about us
Search

About the Biotech & Pharma Industries & Human Biotechnology


The fast-growing biotech industry is playing a dominant role in shaping the development, marketing and use of human biotechnologies. Like the pharmaceutical industry, it profits by developing products aimed at treating disease and restoring health. Although some biotech products and activities are socially and ethically controversial, the industry as a whole tends to oppose public oversight and regulation.

This situation is complicated by increasingly blurred lines between private biotechnology companies and university researchers, between perceptions of serving the public interest and the profit imperatives of private enterprise, and between research and commercialization.

In recent decades, the US Congress has enacted policies that allow controversial patents (such as those on gene sequences and human tissues), and that encourage closer university-corporate relations. These policies have led to a rapid commercialization of biology and medicine, and to a significant number of university-based researchers with financial ties to private companies. Such arrangements allow them to maintain the appearance of serving the public interest while pursuing careers in the private sector.

Private industry is an important player in the development of human biotechnologies. But the lack of a financially independent counterweight like the one that public universities used to provide makes effective oversight and responsible regulation imperative. Given the impact of the biotech industry on public debate, public policy, and all of our lives, its interests must be transparent.



AstraZeneca launches project to sequence 2 million genomesby Heidi LedfordNature NewsApril 22nd, 2016One of the world's largest pharmaceutical companies is partnering with the Wellcome Trust Sanger Institute and Craig Venter's Human Longevity to look for rare genetic differences between individuals.
Save the Mosquitosby Ashley DawsonJacobinApril 22nd, 2016We should fight Zika with better public health, not genetically modified mosquitos.
Japanese scientists given green light to modify fertilized human eggs[citing CGS]RT [Russia Today]April 22nd, 2016A government bioethics panel in Japan is only allowing CRISPR gene editing in human embryos for basic research purposes.
Eric Lander talks CRISPR and the infamous Nobel ‘rule of three’by Joel AchenbachThe Washington PostApril 21st, 2016At the Aspen Institute, Lander urged scientific modesty with new gene editing tools: “We are terrible predictors of the consequences of the changes we make.”
We Still Haven’t Found a Fountain of Youth in Our DNAby Brian AlexanderMIT Technology ReviewApril 21st, 2016The Cypher Genomics project has been attempting to identify genetic variants that contribute to longevity, but so far there's no smoking gun.
Scientists unveil the ‘most clever CRISPR gadget’ so farby Sharon BegleySTATApril 20th, 2016A new "base editing" method attempts to switch out individual letters of DNA (C to T; G to A), but it's usefulness and precision is unclear.
More People Seek Genetic Testing, But There Aren't Enough Counselorsby Todd BookmanNPRApril 18th, 2016The field of precision medicine is facing a bottleneck: "Who will actually interpret and provide those results to patients?"
CRISPR: Pursuit of profit poisons collaborationby Jacob S. SherkowNature April 13th, 2016Overzealous efforts to commercialize technology can damage science.
One Thing that Could Stop the Rise of Gene Editing: Insurance Companiesby Jason KoeblerMotherboard [VICE]April 12th, 2016If insurance companies refuse to cover potential new treatments involving gene editing, precision medicine might be limited to those who can afford the expense.
The trouble with paying for spermby Alana Cattapan & Françoise BaylisThe Star [Toronto]April 9th, 2016The so-called shortage of Canadian sperm is not about men being unwilling to donate without pay.
Displaying 1-10 of 2302  
Next >> 
Last Page » 
« Show Complete List » 


ESPAÑOL | PORTUGUÊS | Русский

home | overview | blog | publications| about us | donate | newsletter | press room | privacy policy

CGS • 1122 University Ave, Suite 100, Berkeley, CA 94702 • • (p) 1.510.665.7760 • (F) 1.510.665.8760